Childhood Cancers

The NexTGen team launches the world's largest CAR-T cell trial for pediatric solid tumors, offering new hope for children with relapsed cancer.

Pediatric Cancer Research Foundation CEO Danielle Fragalla discusses the biological differences in pediatric cancer and the need for treatments designed for developing bodies.

Elena Jeannotte discusses building a community of support for children with cancer and their families, especially during the holiday season.

A young cancer survivor who underwent external beam radiation therapy and brachytherapy at 14 years old discusses her rare diagnosis, side effects and the nonlink to her Turner syndrome.

Neuroblastoma is the most common cancer in infants and most commonly occurs in children younger than 5 years old.

Dena Paluck, whose daughter Laura had osteosarcoma, volunteers with Hopeful Hearts to connect parents of children with cancer to support networks.

Cancer treatments can speed up aging in survivors, according to research, which can contribute to a person's risk for conditions like heart disease.

Childhood cancer treatments can accelerate biological aging which increases survivors’ risk for long-term health issues like heart disease and obesity.

DPOAE testing showed no hearing loss in children with retinoblastoma treated with intra-arterial paraplatin, suggesting preserved cochlear function.

Carly Stafford Dixon, a rare cancer survivor, highlights the need for AYA cancer awareness to improve support, visibility and access to vital resources.

Adolescent and young adult patients with cancer face delayed diagnoses, financial hardships and gaps in specialized care, creating a need for tailored support.

Adolescent and Young Adult Cancer Awareness Week sheds light on the financial hardships young cancer survivors face, including debt and limited assistance.

Researchers have found childhood cancer survivors are at risk of experiencing onset of aging-related disease 17.7 years sooner than the general population.

Treatment with Tafinlar in combination with Mekinist showed what researchers described as “considerable efficacy” among patients with gliomas.

Ann Graham of MIB Agents discussed some of the challenges adolescent and young adult patients deal with after cancer diagnoses.

The FDA approved several drugs in December for the treatment of diseases, including pancreatic adenocarcinoma, lung cancer, skin cancer and graft-versus-host disease.

CURE® highlights some top stories from the ASH Annual Meeting, focusing on B-cell acute lymphoblastic leukemia, multiple myeloma and other blood cancers.

This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease.

Maggie Bushway reflected on her memoir “Pearls: A Memoir on Childhood Cancer and Hope,” and her journey of healing and resilience after brain cancer.

Treatment with bicistronic CD19/CD22 CAR-T cell therapy has shown event-free survival improvements in children with relapsed or refractory B-ALL.

Three cycles of chemotherapy were found to face similar results as six cycles among children with retinoblastoma, a type of cancer of the eye.

My daughter's diagnosis of a rare and aggressive brain tumor at 3 years old made me strongly consider whether or not to have her treated with radiation.

During October, the FDA approved drugs to treat diseases including breast cancer, lung cancer, leukemia and gastric cancer.

From World Series tickets given to a pediatric patient with cancer to the death of David Harris, known as Cochise in “The Warriors,” at the age of 75, here is this week’s cancer news.

Jylamvo is an oral liquid formulation of methotrexate originally approved in 2022 for adults with acute lymphoblastic leukemia, among other diseases.